Skip to main content
Loading

Expanding and transferring regulatory T cells to enhance immune tolerance

17 Jun 2025
Immune Regulation

Autologous vs allogeneic Treg cell therapies - which one first and why?

  • Discuss pros/cons of each one in the context of chronic vs acute diseases

Natural Foxp3+ CD4 Tregs vs induced or forced-expressed Foxp3+ CD4 Tregs vs Tr1 Tregs.

  • Comparative analysis with difference/pros/cons, MOA or indication

Navigating specificity, avidity and HLA-restriction to fine-tune  TCR Treg cell therapy 

  • Polyclonal vs ag-specific strategies and their limitations

Industry Expert
Seng-Lai (Thomas) Tan, Chief Scientific Officer - TFC Therapeutics